Necroptosis is an alternative cell death pathway different from the more familiar caspase-dependent apoptosis. It involves three kinases - RIPK1, MLKL and RIPK3 of which RIPK1 appears easiest to target. GSK has a RIPK1 compound in trials in IBD, so it has potential applications outside the CNS.